NL301155I2 - abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Info

Publication number: NL301155I2
Authority: NL; Netherlands
Prior art keywords: abrocitinib; optionally; pharmaceutically acceptable; acceptable salt; salt
Prior art date: 2013-02-22

Application number

NL301155C

Other languages

English (en)

Other versions

NL301155I1 (nl

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-22

Filing date

2021-12-22

Publication date

2022-02-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301155(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-12-22 Application filed by Pfizer filed Critical Pfizer

2021-12-22 Publication of NL301155I1 publication Critical patent/NL301155I1/nl

2022-02-23 Publication of NL301155I2 publication Critical patent/NL301155I2/nl

Links

IUEWXNHSKRWHDY-PHIMTYICSA-N abrocitinib Chemical compound C1[C@@H](NS(=O)(=O)CCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 IUEWXNHSKRWHDY-PHIMTYICSA-N 0.000 title 1
229940121519 abrocitinib Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Hematology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

NL301155C 2013-02-22 2021-12-22 abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301155I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361767947P	2013-02-22	2013-02-22
PCT/IB2014/058889 WO2014128591A1 (en)	2013-02-22	2014-02-11	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)

Publications (2)

Publication Number	Publication Date
NL301155I1 NL301155I1 (nl)	2021-12-22
NL301155I2 true NL301155I2 (nl)	2022-02-23

Family

ID=50151346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301155C NL301155I2 (nl)	2013-02-22	2021-12-22	abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Country Status (48)

Country	Link
US (3)	US9035074B2 (nl)
EP (2)	EP2958921B1 (nl)
JP (2)	JP6145179B2 (nl)
KR (1)	KR101787858B1 (nl)
CN (2)	CN105008362B (nl)
AP (1)	AP2015008664A0 (nl)
AR (1)	AR094857A1 (nl)
AU (1)	AU2014220357B2 (nl)
BR (1)	BR112015019634B1 (nl)
CA (1)	CA2900703C (nl)
CL (1)	CL2015002303A1 (nl)
CR (1)	CR20150395A (nl)
CU (1)	CU24275B1 (nl)
CY (3)	CY1119502T1 (nl)
DK (2)	DK2958921T3 (nl)
DO (1)	DOP2015000206A (nl)
EA (1)	EA027879B1 (nl)
ES (2)	ES2713052T3 (nl)
FR (1)	FR22C1006I2 (nl)
GE (1)	GEP201606600B (nl)
HR (2)	HRP20171599T2 (nl)
HU (3)	HUE041778T2 (nl)
IL (1)	IL240132B (nl)
LT (3)	LT2958921T (nl)
LU (1)	LUC00261I2 (nl)
MA (1)	MA38347A1 (nl)
MD (1)	MD4735C1 (nl)
ME (2)	ME03301B (nl)
MX (1)	MX374338B (nl)
MY (1)	MY177476A (nl)
NL (1)	NL301155I2 (nl)
NO (2)	NO3052752T3 (nl)
NZ (1)	NZ710411A (nl)
PE (1)	PE20151764A1 (nl)
PH (1)	PH12015501779A1 (nl)
PL (2)	PL3290421T3 (nl)
PT (2)	PT3290421T (nl)
PY (1)	PY1407086A (nl)
RS (2)	RS58245B1 (nl)
SG (1)	SG11201505816UA (nl)
SI (2)	SI3290421T1 (nl)
TN (1)	TN2015000355A1 (nl)
TR (1)	TR201902525T4 (nl)
TW (1)	TWI507408B (nl)
UA (1)	UA111804C2 (nl)
UY (1)	UY35337A (nl)
WO (1)	WO2014128591A1 (nl)
ZA (1)	ZA201505454B (nl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3915367A1 (en)	2010-08-18	2021-12-01	BioSplice Therapeutics, Inc.	Diketones and hydroxyketones as catenin signaling pathway activators
US10172789B2 (en)	2013-01-24	2019-01-08	Palvella Therapeutics Llc	Compositions for transdermal delivery of mTOR inhibitors
PE20151721A1 (es)	2013-02-22	2015-12-07	Samumed Llc	Y-dicetonas como activadores de la ruta de senalizacion de wnt/b-catenina
EA027879B1 (ru)	2013-02-22	2017-09-29	Пфайзер Инк.	ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
AU2021281643B2 (en) *	2014-02-11	2024-02-15	Pfizer Inc.	Pyrrolo(2,3-d)pyrimidine derivatives
WO2016024185A1 (en) *	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
DK3206686T3 (da)	2014-08-20	2019-12-16	Samumed Llc	Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
DK3305788T3 (da) *	2015-05-29	2020-09-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus-kinase-hæmmer
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (zh)	2015-10-16	2023-06-23	艾伯维公司	制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106831779B (zh) *	2015-11-28	2019-07-19	南昌弘益药业有限公司	一类jak激酶抑制剂的新化合物
US10973913B2 (en)	2016-02-16	2021-04-13	Washington University	JAK inhibitors and uses thereof
WO2018129364A1 (en)	2017-01-06	2018-07-12	Palvella Therapeutics Llc	Anhydrous compositions of mtor inhibitors and methods of use
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
CR20200464A (es)	2018-03-08	2021-04-14	Incyte Corp	Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en)	2018-07-02	2020-01-09	Incyte Corporation	AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP3817743A4 (en)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
EP3817810B1 (en)	2018-07-06	2025-09-17	Pfizer Inc.	Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
JP2022506682A (ja) *	2018-11-05	2022-01-17	アビスタファーマソリューションズ，インコーポレーテッド	化合物
DK3915989T3 (da) *	2019-01-30	2023-09-18	Felicamed Biotechnology Co Ltd	Jak inhibitor and preparation method therefor
KR102820235B1 (ko)	2019-02-15	2025-06-16	화이자 인코포레이티드	결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
EP3939979A4 (en)	2019-03-14	2022-04-06	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	JAK-KINASE INHIBITOR, PROCESS FOR ITS PRODUCTION AND MEDICAL APPLICATIONS
WO2020261041A1 (en) *	2019-06-27	2020-12-30	Glenmark Life Sciences Limited	Process for preparation of abrocitinib
KR20220059519A (ko)	2019-09-11	2022-05-10	화이자 인코포레이티드	키나제 억제제에 의한 한선염의 치료
CA3156007A1 (en)	2019-09-27	2021-04-01	Disc Medicine, Inc.	METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
BR112022020020A2 (pt)	2020-04-04	2022-11-22	Pfizer	Métodos de tratamento da doença do coronavírus 2019
CN113637018A (zh)	2020-04-27	2021-11-12	苏州晶云药物科技股份有限公司	磺酰胺类化合物的晶型及其制备方法
ES3075793T3 (en)	2020-05-13	2026-08-07	Disc Medicine Inc	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en)	2020-05-13	2022-11-17	AbbVie Deutschland GmbH & Co. KG	Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
WO2022053931A1 (en)	2020-09-08	2022-03-17	Galderma Holding SA	Novel jak inhibitor compounds, method for synthesizing same and use thereof
EP4210828A1 (en)	2020-09-11	2023-07-19	Galderma Holding SA	Novel jak inhibitor compounds, method for synthesizing same and use thereof
CA3210150A1 (en)	2021-02-02	2022-08-11	Pfizer Inc.	Dosing regime for treatment of chronic hand eczema
KR20230019801A (ko) *	2021-08-02	2023-02-09	한국화학연구원	신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN118255769A (zh) *	2022-12-28	2024-06-28	格格巫（珠海）生物科技有限公司	一种立体异构体的制备方法及中间体
ES2993658B2 (es)	2023-06-27	2025-07-02	Moehs Iberica Sl	(3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
WO2025008772A2 (en)	2023-07-06	2025-01-09	Pfizer Ireland Pharmaceuticals	Improved manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof
ES3040374B2 (es)	2024-04-30	2026-07-09	Moehs Iberica Sl	Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3037980A (en)	1955-08-18	1962-06-05	Burroughs Wellcome Co	Pyrrolopyrimidine vasodilators and method of making them
BR9307646A (pt)	1992-12-17	1999-05-25	Pfizer	Pirrolopirimidinas como antagonistas de crf
JPH06329675A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH06329674A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH08134068A (ja)	1994-11-02	1996-05-28	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en)	1996-02-12	2000-04-18	Pfizer Inc.	Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en)	1998-06-02	2004-02-03	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
AU3951899A (en)	1998-06-19	2000-01-05	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
JP2002543200A (ja)	1999-04-30	2002-12-17	ニューロゲンコーポレイション	９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド
US6664252B2 (en)	1999-12-02	2003-12-16	Osi Pharmaceuticals, Inc.	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
OA12118A (en)	1999-12-10	2006-05-04	Pfizer Prod Inc	PyrroloÄ2,3-dÜpyrimidine compounds.
US20030187261A1 (en)	2000-01-07	2003-10-02	Libor Havlicek	Purine derivatives, process for their preparation and use thereof
OA12292A (en)	2000-06-26	2003-11-11	Pfizer Prod Inc	PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en)	2000-12-01	2004-01-06	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
JP2005529062A (ja)	2001-11-30	2005-09-29	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	アデノシンａ１及びａ３受容体に特異的な化合物とその使用
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003299901A1 (en)	2002-10-04	2004-05-04	Merck And Co., Inc.	Thrombin inhibitors
RS20050380A (sr)	2002-11-21	2007-11-15	Pfizer Products Inc.,	Derivati 3-aminopiperidina i postupci njihove proizvodnje
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2007012953A2 (en)	2005-07-29	2007-02-01	Pfizer Products Inc.	Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
JP2007091649A (ja)	2005-09-29	2007-04-12	Taisho Pharmaceut Co Ltd	ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) *	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
US20100273776A1 (en)	2006-03-29	2010-10-28	FOLDRx PHARMACEUTICALS, INC	Inhibition of alpha-synuclein toxicity
US20080200458A1 (en)	2007-01-18	2008-08-21	Joseph Barbosa	Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en)	2007-01-18	2008-07-24	Lexicon Pharmaceuticals, Inc.	Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2009062118A2 (en)	2007-11-07	2009-05-14	Foldrx Pharmaceuticals, Inc.	Modulation of protein trafficking
WO2009060278A1 (en)	2007-11-08	2009-05-14	Pfizer Inc.	Cyclobutyl carboxylic acid derivatives
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
RS53382B (sr)	2008-08-20	2014-10-31	Zoetis Llc	Jedinjenja pirol [2,3-d]pirimidina
KR20110044304A (ko)	2008-09-18	2011-04-28	화이자 리미티드	치료에 유용한 아마이드 화합물
AU2010308028A1 (en)	2009-10-15	2012-04-19	Pfizer Inc.	Pyrrolo[2,3-d] pyrimidine compounds
EP4782062A2 (en)	2009-12-01	2026-07-29	AbbVie Inc.	Novel tricyclic compounds
CA2782720A1 (en)	2009-12-18	2011-06-23	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds
CN102712640A (zh)	2010-01-12	2012-10-03	弗·哈夫曼-拉罗切有限公司	三环杂环化合物、其组合物和应用方法
WO2011104652A2 (en)	2010-02-24	2011-09-01	Pfizer Inc.	Veterinary compositions
WO2012009649A1 (en)	2010-07-16	2012-01-19	Anderson Gaweco	Mif inhibitors and their uses
CN103097340B (zh)	2010-07-16	2018-03-16	安吉奥斯医药品有限公司	治疗活性组合物及其使用方法
CN103391939B (zh)	2010-12-03	2016-03-09	Epizyme股份有限公司	作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
US8987307B2 (en)	2011-03-03	2015-03-24	Hoffmann-La Roche Inc.	3-amino-pyridines as GPBAR1 agonists
CA2833507A1 (en)	2011-06-07	2012-12-13	Dainippon Sumitomo Pharma Co., Ltd.	Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
JP2013010719A (ja)	2011-06-30	2013-01-17	Dainippon Sumitomo Pharma Co Ltd	ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
JP6075736B2 (ja) *	2011-12-21	2017-02-08	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途
WO2014011911A2 (en)	2012-07-11	2014-01-16	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
PT2874630T (pt)	2012-07-20	2019-01-31	Zoetis Services Llc	Regime de dosagem para inibidores de janus quinase (jak)
JP2014133739A (ja)	2012-12-12	2014-07-24	Dainippon Sumitomo Pharma Co Ltd	インダゾール誘導体またはピロロピリジン誘導体からなる医薬
EA027879B1 (ru) *	2013-02-22	2017-09-29	Пфайзер Инк.	ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2016024185A1 (en)	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

2014
- 2014-02-11 EA EA201591255A patent/EA027879B1/ru unknown
- 2014-02-11 ME MEP-2019-6A patent/ME03301B/me unknown
- 2014-02-11 NZ NZ710411A patent/NZ710411A/en unknown
- 2014-02-11 MA MA38347A patent/MA38347A1/fr unknown
- 2014-02-11 HU HUE17191163A patent/HUE041778T2/hu unknown
- 2014-02-11 DK DK14705887.9T patent/DK2958921T3/da active
- 2014-02-11 DK DK17191163.9T patent/DK3290421T3/en active
- 2014-02-11 SI SI201431068T patent/SI3290421T1/sl unknown
- 2014-02-11 WO PCT/IB2014/058889 patent/WO2014128591A1/en not_active Ceased
- 2014-02-11 LT LTEP14705887.9T patent/LT2958921T/lt unknown
- 2014-02-11 PL PL17191163T patent/PL3290421T3/pl unknown
- 2014-02-11 PL PL14705887T patent/PL2958921T3/pl unknown
- 2014-02-11 PE PE2015001766A patent/PE20151764A1/es active IP Right Grant
- 2014-02-11 ES ES17191163T patent/ES2713052T3/es active Active
- 2014-02-11 JP JP2015558572A patent/JP6145179B2/ja active Active
- 2014-02-11 CU CUP2015000078A patent/CU24275B1/xx unknown
- 2014-02-11 EP EP14705887.9A patent/EP2958921B1/en active Active
- 2014-02-11 SG SG11201505816UA patent/SG11201505816UA/en unknown
- 2014-02-11 RS RS20190097A patent/RS58245B1/sr unknown
- 2014-02-11 LT LTEP17191163.9T patent/LT3290421T/lt unknown
- 2014-02-11 HU HUE14705887A patent/HUE037192T2/hu unknown
- 2014-02-11 HR HRP20171599TT patent/HRP20171599T2/hr unknown
- 2014-02-11 CN CN201480009783.8A patent/CN105008362B/zh active Active
- 2014-02-11 AU AU2014220357A patent/AU2014220357B2/en active Active
- 2014-02-11 SI SI201430459T patent/SI2958921T1/sl unknown
- 2014-02-11 PT PT17191163T patent/PT3290421T/pt unknown
- 2014-02-11 KR KR1020157022489A patent/KR101787858B1/ko active Active
- 2014-02-11 AP AP2015008664A patent/AP2015008664A0/xx unknown
- 2014-02-11 CA CA2900703A patent/CA2900703C/en active Active
- 2014-02-11 GE GEAP201413916A patent/GEP201606600B/en unknown
- 2014-02-11 CN CN201710440379.1A patent/CN107089985B/zh active Active
- 2014-02-11 MD MDA20150073A patent/MD4735C1/ro active IP Right Grant
- 2014-02-11 BR BR112015019634-9A patent/BR112015019634B1/pt active IP Right Grant
- 2014-02-11 MY MYPI2015702431A patent/MY177476A/en unknown
- 2014-02-11 ES ES14705887.9T patent/ES2647525T3/es active Active
- 2014-02-11 EP EP17191163.9A patent/EP3290421B1/en active Active
- 2014-02-11 RS RS20171095A patent/RS56503B1/sr unknown
- 2014-02-11 MX MX2015010928A patent/MX374338B/es active IP Right Grant
- 2014-02-11 TR TR2019/02525T patent/TR201902525T4/tr unknown
- 2014-02-11 ME MEP-2017-246A patent/ME02904B/me unknown
- 2014-02-11 PT PT147058879T patent/PT2958921T/pt unknown
- 2014-02-19 US US14/183,946 patent/US9035074B2/en active Active
- 2014-02-19 TW TW103105469A patent/TWI507408B/zh active
- 2014-02-20 UY UY0001035337A patent/UY35337A/es not_active Application Discontinuation
- 2014-02-21 AR ARP140100561A patent/AR094857A1/es active IP Right Grant
- 2014-02-21 PY PY201401407086A patent/PY1407086A/es unknown
- 2014-09-24 NO NO14789648A patent/NO3052752T3/no unknown
- 2014-11-02 UA UAA201507511A patent/UA111804C2/uk unknown
2015
- 2015-04-21 US US14/691,606 patent/US9545405B2/en active Active
- 2015-05-18 US US14/715,046 patent/US9549929B2/en active Active
- 2015-07-23 IL IL240132A patent/IL240132B/en active IP Right Grant
- 2015-07-29 ZA ZA2015/05454A patent/ZA201505454B/en unknown
- 2015-07-30 CR CR20150395A patent/CR20150395A/es unknown
- 2015-08-12 PH PH12015501779A patent/PH12015501779A1/en unknown
- 2015-08-17 CL CL2015002303A patent/CL2015002303A1/es unknown
- 2015-08-18 TN TN2015000355A patent/TN2015000355A1/fr unknown
- 2015-08-21 DO DO2015000206A patent/DOP2015000206A/es unknown
2017
- 2017-05-11 JP JP2017094676A patent/JP2017165762A/ja active Pending
- 2017-10-26 CY CY20171101116T patent/CY1119502T1/el unknown
2019
- 2019-01-23 HR HRP20190152TT patent/HRP20190152T1/hr unknown
- 2019-01-30 CY CY20191100127T patent/CY1121468T1/el unknown
2021
- 2021-12-22 NL NL301155C patent/NL301155I2/nl unknown
2022
- 2022-01-12 CY CY2022003C patent/CY2022003I2/el unknown
- 2022-01-17 HU HUS2200003C patent/HUS2200003I1/hu unknown
- 2022-01-26 LT LTPA2022502C patent/LTC2958921I2/lt unknown
- 2022-02-01 NO NO2022004C patent/NO2022004I1/no unknown
- 2022-02-10 FR FR22C1006C patent/FR22C1006I2/fr active Active
- 2022-05-13 LU LU00261C patent/LUC00261I2/fr unknown

Also Published As

Publication number	Publication date
PL2958921T3 (pl)	2018-01-31
CR20150395A (es)	2015-09-23
LT2958921T (lt)	2017-11-27
BR112015019634B1 (pt)	2022-09-20
EP3290421B1 (en)	2019-01-02
GEP201606600B (en)	2017-01-10
US20140243312A1 (en)	2014-08-28
WO2014128591A1 (en)	2014-08-28
US9545405B2 (en)	2017-01-17
AU2014220357B2 (en)	2017-04-27
HRP20190152T1 (hr)	2019-03-22
CY2022003I1 (el)	2022-03-24
CY2022003I2 (el)	2022-03-24
SI2958921T1 (sl)	2017-12-29
MY177476A (en)	2020-09-16
ES2647525T3 (es)	2017-12-22
LTC2958921I2 (nl)	2024-03-25
TWI507408B (zh)	2015-11-11
CN107089985B (zh)	2019-06-07
LT3290421T (lt)	2019-02-25
CY1119502T1 (el)	2018-03-07
HUE041778T2 (hu)	2019-05-28
PE20151764A1 (es)	2015-12-03
LUC00261I2 (nl)	2025-04-25
EP2958921B1 (en)	2017-09-20
LTPA2022502I1 (nl)	2022-03-10
CU20150078A7 (es)	2016-01-29
EA027879B1 (ru)	2017-09-29
PH12015501779B1 (en)	2015-12-02
IL240132A0 (en)	2015-09-24
TN2015000355A1 (fr)	2017-01-03
HK1213881A1 (zh)	2016-07-15
PT2958921T (pt)	2017-11-20
JP2016509049A (ja)	2016-03-24
AU2014220357A1 (en)	2015-08-06
SI3290421T1 (sl)	2019-03-29
EP3290421A1 (en)	2018-03-07
NO3052752T3 (nl)	2018-06-16
KR101787858B1 (ko)	2017-10-18
CA2900703C (en)	2017-11-28
IL240132B (en)	2020-09-30
MD4735C1 (ro)	2021-07-31
TR201902525T4 (tr)	2019-03-21
CN107089985A (zh)	2017-08-25
JP6145179B2 (ja)	2017-06-07
DK3290421T3 (en)	2019-03-18
DOP2015000206A (es)	2016-02-15
SG11201505816UA (en)	2015-09-29
PY1407086A (es)	2017-10-02
MA38347A1 (fr)	2017-10-31
NO2022004I1 (no)	2022-02-01
JP2017165762A (ja)	2017-09-21
MD4735B1 (ro)	2020-12-31
KR20150109434A (ko)	2015-10-01
CA2900703A1 (en)	2014-08-28
CN105008362B (zh)	2017-06-06
EP2958921A1 (en)	2015-12-30
HUS2200003I1 (hu)	2022-02-28
HRP20171599T2 (hr)	2018-11-16
EA201591255A1 (ru)	2016-03-31
AP2015008664A0 (en)	2015-08-31
US9035074B2 (en)	2015-05-19
CL2015002303A1 (es)	2015-12-18
UY35337A (es)	2014-09-30
RS56503B1 (sr)	2018-02-28
NL301155I1 (nl)	2021-12-22
HRP20171599T1 (hr)	2017-12-01
UA111804C2 (uk)	2016-06-10
TW201443055A (zh)	2014-11-16
ZA201505454B (en)	2016-07-27
MX2015010928A (es)	2015-10-29
CN105008362A (zh)	2015-10-28
CY1121468T1 (el)	2020-05-29
PH12015501779A1 (en)	2015-12-02
US9549929B2 (en)	2017-01-24
PL3290421T3 (pl)	2019-05-31
MD20150073A2 (ro)	2016-01-31
FR22C1006I1 (fr)	2022-03-25
HUE037192T2 (hu)	2018-08-28
NZ710411A (en)	2017-11-24
PT3290421T (pt)	2019-03-01
ES2713052T3 (es)	2019-05-17
US20150225408A1 (en)	2015-08-13
MX374338B (es)	2025-03-06
ME03301B (me)	2019-07-20
RS58245B1 (sr)	2019-03-29
FR22C1006I2 (fr)	2023-01-27
CU24275B1 (es)	2017-10-05
ME02904B (me)	2018-04-20
DK2958921T3 (da)	2017-11-06
US20150246048A1 (en)	2015-09-03
BR112015019634A2 (pt)	2019-12-17
AR094857A1 (es)	2015-09-02

Publication	Publication Date	Title
NL301341I2 (nl)	2025-10-02	eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301245I2 (nl)	2023-11-20	Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301161I2 (nl)	2022-04-06	zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301327I2 (nl)	2025-07-17	Belzutifan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder belzutifan
NL301238I2 (nl)	2023-10-04	Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301149I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301329I2 (nl)	2025-09-09	Lazertinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301006I2 (nl)	2020-04-14	Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301279I2 (nl)	2024-08-01	Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301342I2 (nl)	2025-11-10	Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301292I2 (nl)	2024-10-30	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl)	2024-01-10	mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NL301326I2 (nl)	2025-07-31	imetelstat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301373I2 (nl)	2026-03-30	Vimseltinib of optioneel een farmaceutisch aanvaardbaar zout daarvan
NL301370I2 (nl)	2026-03-30	vorasidenib of een farmaceutisch aanvaardbaar zout of hydraat daarvan
NL301224I2 (nl)	2023-08-16	Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2022004I1 (no)	2022-02-01	abrocitinib, or a pharmaceutically acceptable salt thereof
NL301369I2 (nl)	2026-03-30	resmetirom of een farmaceutisch aanvaardbaar zout daarvan
NL301276I2 (nl)	2024-06-24	omaveloxolon of een farmaceutisch aanvaardbaar zout daarvan
NL301131I2 (nl)	2021-10-25	pemigatinib of een farmaceutisch aanvaardbaar zout daarvan
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NL301260I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301047I2 (nl)	2023-08-01	fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride